Investor News
Indivior RBP-6000 NDA Acceptance with Priority Review Designation
Indivior PLC Announces FDA Acceptance with Priority Review Designation of RBP-6000 Buprenorphine Monthly Depot New…
Read moreIndivior’s NALSCUE® Receives Marketing Authorization from French Regulatory Agency ANSM
French Regulatory Agency ANSM Approves Marketing Authorisation for Indivior’s NALSCUE® (Naloxone Hydrochloride) Nasal Spray for…
Read moreIndivior H1 2017 Financial Results
Strong H1 2017 Financial Results and FY 2017 Guidance Raised H1 2017 net revenue of…
Read morePresentation: H1 2017 Financial Results
Read moreWebcast Event: H1 2017 Financial Results
Read moreIndivior to Announce Half Year 2017 Results on July 27th
Slough, UK, and Richmond, VA, 13 July 2017 – Indivior PLC (LON: INDV) today announced…
Read morePresentation: RBP-6000 Buprenorphine Monthly Depot Phase 3 Clinical Results Investor Event on June 29th, 2017
To view the presentation click here.
Read moreWebcast Event: RBP-6000 Investor Event
To view the webcast click here.
Read moreReminder RBP-6000 Investor Event Announcement
To view the presentation click here. To view the webcast event click here. Indivior to…
Read morePresentation: RBP-6000 Data Presented in Late-Breaking Research Oral Session at CPDD 79th Annual Scientific Meeting on June 21, 2017
Click here to view the presentation.
Read more